Search for contacts, projects,
courses and publications

Petr Cejka


Petr Cejka received his Master’s degree in 2000 from the   Charles University in Prague and PhD in 2004 from the University of Zurich. During his PhD studies with Prof. Josef Jiricny, Petr Cejka studied the function of the mismatch repair system in human cells, as well as how mismatch repair mediates the sensitivity of DNA methylating agents used in anti-cancer therapy. Petr Cejka then received a postdoctoral fellowship from the Swiss National    .. Science Foundation to move to the laboratory of Prof. Stephen Kowalczykowski at the University of California, Davis, US. Dr. Cejka received extensive training in protein biochemistry and contributed to our understanding of homologous recombination. In 2011, Dr. Cejka was awarded Assistant Professorship from the Swiss National Science Foundation and returned to the University of Zurich as an independent researcher. In 2016, Prof. Cejka   moved to the Institute for Research in Biomedicine, and later became associate professor at USI. The research in Prof. Cejka’s laboratory is focused on  understanding how cells repair broken DNA, with a focus on a pathway termed homologous recombination. For his scientific achievements, Prof. Cejka received the Dr. Ernst Th. Jucker Award 2015 for contributions to cancer  research and in 2017 the Friedrich Miescher Award from the LS2 section of Molecular and Cellular Biosciences. Prof. Cejka received an ERC (European Research Council) consolidator grant (2016) and an ERC advanced grant (2021).


First steps in homologous recombination: DNA end resection

Homologous recombination is initiated by the nucleolytic degradation (resection) of the 5'-terminated DNA strand of the DNA break. This leads to the formation of 3'-tailed DNA, which becomes a substrate for the strand exchange protein RAD51 and primes DNA synthesis during the downstream events in the recombination pathway.  DNA end resection thus represents a key process that commits the repair of DNA breaks into recombination. Research from multiple laboratories established that DNA end resection is in most cases a two-step process. It is initiated by the nucleolytic degradation of DNA that is at first limited to the vicinity of the broken DNA end. This is carried out by the Mre11-Rad50-Xrs2 (MRX) complex and Sae2 proteins in yeast, and MRE11-RAD50-NBS1 (MRN) and CtIP proteins in human cells. We could reconstitute these reactions in vitro, and demonstrated that Sae2 and CtIP stimulate a cryptic endonuclease activity within the yeast MRX or human MRN complex, respectively. The activity of Sae2/CtIP is absolutely dependent on its phosphorylation. The reconstituted DNA clipping reaction allows us to investigate the mechanism of this process as well as its regulation by posttranslational modifications and additional protein co-factors.

Downstream of MRX-Sae2 and MRN-CtIP, which process only a limited length of DNA, DNA end resection is further catalyzed by Sgs1-Dna2 or Exo1 in yeast and BLM-DNA2, WRN-DNA2 or EXO1 in human cells. We are interested how the functions of these factors integrate in protein complexes to form molecular machines that are uniquely capable to resect long lengths of DNA, which is required for homologous recombination. We are specifically interested in the Dna2 enzyme, and could show that both yeast Dna2 and human DNA2 possess a cryptic helicase activity. We now investigate how the motor activity of Dna2 promotes DNA end resection, as well as how it is regulated in cells. Finally, as some of these enzymes are upregulated in various human cancers, we are also searching for small molecules capable to inhibit these pathways.

  Promotion of genetic diversity in meiosis: resolution of recombination intermediates

Promotion of genetic diversity is a key function of sexual reproduction. At the molecular level, this is controlled by the homologous recombination machinery, which exchanges (recombines) DNA fragments between the maternal and paternal genomes. During this process, joint molecules form between the 'mum' and 'dad' chromosomes, leading to intermediates termed double Holliday junctions. These joint molecules are then processed in a way that results in the physical exchange of genetic information between the two recombining chromosomes. This so‐called crossover is an integral and essential part of the meiotic cell division. Results from genetic, cell biological and cytological experiments identified the Mlh1‐Mlh3 heterodimer as part of a protein complex that is required for the generation of crossovers during meiotic homologous recombination. However, the mechanism of this reaction is completely unknown. The aim of our research is to analyze the behavior of the purified recombinant Mlh1­‐Mlh3 complex as well that of its partners in the processing of double Holliday junctions. We want to show how Mlh1‐Mlh3 can cleave these structures into exclusively crossover recombination products, and therefore explain the molecular mechanism underlying the generation of diversity in meiosis.

So far, we successfully expressed and purified the yeast Mlh1-­Mlh3 and human MLH1-MLH3 recombinant proteins into near homogeneity. We could show that the recombinant MutLγ is indeed a nuclease that nicks double­‐stranded DNA in the presence of manganese, similarly to the mismatch repair specific MutLα nuclease. MutLγ binds DNA with a high affinity, and shows a marked preference for Holliday junctions, in agreement with its anticipated activity in their processing. Specific DNA recognition has never been observed with any other eukaryotic MutL homologue. Mismatch repair specific MutLα shows no binding preference to mismatched DNA. MutLγ thus represents a new paradigm for the function of the eukaryotic MutL protein family. Unfortunately, to date, we have not seen any activity on joint molecule intermediates (such as Holliday junctions) in the presence of physiological manganese metal cofactor. This will likely require interplay of Mlh1-Mlh3 with other cellular factors (such as Exo1, Msh4-Msh5, etc.), and is the subject of vigorous research in the laboratory at present.